(Reuters) - NEW YORK/LOS ANGELES, July 26 - Amgen Inc. on
Thursday posted quarterly profit that topped Wall Street
expectations, even as sales of its biggest drug, Aranesp, fell
19 percent in the United States amid safety concerns.
The company also announced positive breast cancer data
about its most important experimental drug, denosumab, and
issued a full-year profit forecast above analysts' estimates.
Its shares rose 1.9 percent in after-hours trading.
Read more at Reuters.com Market News
Thursday posted quarterly profit that topped Wall Street
expectations, even as sales of its biggest drug, Aranesp, fell
19 percent in the United States amid safety concerns.
The company also announced positive breast cancer data
about its most important experimental drug, denosumab, and
issued a full-year profit forecast above analysts' estimates.
Its shares rose 1.9 percent in after-hours trading.
Read more at Reuters.com Market News
No comments:
Post a Comment